We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
SARS-CoV-2 Antibody Dynamics after COVID-19 Vaccination and Infection: A Real-World Cross-Sectional Analysis.
- Authors
Yorsaeng, Ritthideach; Atsawawaranunt, Kamolthip; Suntronwong, Nungruthai; Kanokudom, Sitthichai; Chansaenroj, Jira; Assawakosri, Suvichada; Nilyanimit, Pornjarim; Aeemjinda, Ratchadawan; Khanarat, Nongkanok; Wongsrisang, Lakkhana; Auphimai, Chompoonut; Vichaiwattana, Preeyaporn; Klinfueng, Sirapa; Thongmee, Thanunrat; Srimuan, Donchida; Thatsanathorn, Thaksaporn; Sudhinaraset, Natthinee; Wanlapakorn, Nasamon; Poovorawan, Yong
- Abstract
The Coronavirus disease 2019 (COVID-19) pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), continues to surge despite the widespread use of vaccination. In Thailand, more than 77% and 39% of the population received two doses and three doses of COVID-19 vaccines as of December 2022, respectively. In addition, during the Omicron predominant period in 2022, more than 70% of Thai individuals have been infected. To gain comprehensive insight into SARS-CoV-2 antibody dynamics following vaccination or following vaccination and infection (hybrid immunity), we performed a cross-sectional analysis of sera samples from individuals who received COVID-19 vaccination and/or have been infected with COVID-19 in Thailand between January 2021 and December 2022. A total of 4126 samples were collected. Humoral immunity was evaluated by quantifying the immunoglobulin (including IgG, IgM, and IgA isotypes) specific to the SARS-CoV-2 receptor-binding domain (RBD) or Ig anti-RBD. The results showed that individuals who received two-dose vaccination alone had lower levels of Ig anti-RBD, which rapidly waned over time. To restore the waning antibody, a third dose vaccination is recommended for uninfected individuals who have only received 2 doses.
- Subjects
THAILAND; SARS-CoV-2; COVID-19; COVID-19 vaccines; CROSS-sectional method; THAI people
- Publication
Vaccines, 2023, Vol 11, Issue 7, p1184
- ISSN
2076-393X
- Publication type
Article
- DOI
10.3390/vaccines11071184